{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:55:12Z","timestamp":1788472512834,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007698","name":"Sociedade Beneficente Israelita Brasileira Albert Einstein","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007698","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcyt.2026.102079","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:23:08Z","timestamp":1770312188000},"page":"102079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Umbilical cord blood\u2212derived natural killer cells as a viable and potent source for adoptive cell therapy"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2418-4863","authenticated-orcid":false,"given":"Raquel de Melo","family":"Alves-Paiva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa L.","family":"Coa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3864-7796","authenticated-orcid":false,"given":"Julia T.","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamile Ramos","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana A. P","family":"de Godoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheli Severo","family":"Sielski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Cardoso","family":"Zanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise C.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-6225","authenticated-orcid":false,"given":"Oswaldo Keith","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mauro","family":"Kutner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-5310","authenticated-orcid":false,"given":"Nelson","family":"Hamerschlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucila N.","family":"Kerbauy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1205","key":"10.1016\/j.jcyt.2026.102079_bib0001","article-title":"Cancer immunotherapy based on natural killer cells: current progress and new opportunities","volume":"10","author":"Hu","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102079_bib0002","series-title":"Antileukemic activity of natural killer (NK) cell","first-page":"297","article-title":"Atividade antileuc\u00eamica das c\u00e9lulas natural killer","author":"Almeida-Oliveira","year":"2008"},{"key":"10.1016\/j.jcyt.2026.102079_bib0003","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1034\/j.1600-065X.2002.19004.x","article-title":"The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism","volume":"190","author":"Hsu","year":"2002","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jcyt.2026.102079_bib0004","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/asheducation-2013.1.247","article-title":"Therapeutic applications: natural killer cells in the clinic","volume":"2013","author":"Miller","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"18","key":"10.1016\/j.jcyt.2026.102079_bib0005","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1158\/0008-5472.CAN-10-3211","article-title":"Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2","volume":"71","author":"Textor","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102079_bib0006","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","article-title":"Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation","volume":"94","author":"Ruggeri","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102079_bib0007","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3389\/fimmu.2017.01330","article-title":"The more, the better: \"do the right thing\" for natural killer immunotherapy in acute myeloid leukemia","volume":"8","author":"Parisi","year":"2017","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102079_bib0008","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102079_bib0009","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3389\/fimmu.2019.02357","article-title":"Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells","volume":"10","author":"Carlsten","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102079_bib0010","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00432-017-2568-2","article-title":"Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia","volume":"144","author":"Wang","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102079_bib0011","doi-asserted-by":"crossref","first-page":"42569","DOI":"10.18632\/oncotarget.5559","article-title":"NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance","volume":"6","author":"Martner","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcyt.2026.102079_bib0012","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fimmu.2015.00564","article-title":"Increased NK cell maturation in patients with acute myeloid leukemia","volume":"6","author":"Chretien","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102079_bib0013","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3390\/jcm8101557","article-title":"NK cells in the treatment of hematological malignancies","volume":"8","author":"Gonzalez-Rodriguez","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcyt.2026.102079_bib0014","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.19.1.197","article-title":"Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis","volume":"19","author":"Moretta","year":"2001","journal-title":"Ann Rev Immunol"},{"issue":"930","key":"10.1016\/j.jcyt.2026.102079_bib0015","article-title":"Developmental and functional control of natural killer cells by cytokines","volume":"8","author":"Wu","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102079_bib0016","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-1-4939-3684-7_14","article-title":"Expansion of NK cells using genetically engineered K562 feeder cells","volume":"1441","author":"Phan","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jcyt.2026.102079_bib0017","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4939-9728-2_12","article-title":"An improved method to produce clinical-scale natural killer cells from human pluripotent stem cells","volume":"2048","author":"Zhu","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102079_bib0018","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/cmi.2012.17","article-title":"Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy","volume":"9","author":"Luevano","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jcyt.2026.102079_bib0019","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-020-00996-x","article-title":"Natural killer cell-based immunotherapy for acute myeloid leukemia","volume":"13","author":"Xu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2026.102079_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584099","article-title":"Cord-blood natural killer cell-based immunotherapy for cancer","volume":"11","author":"Zhao","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102079_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102079_bib30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/imr.12129","article-title":"Human cell-based artificial antigen-presenting cells for cancer immunotherapy","volume":"257","author":"Butler","year":"2014","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102079_bib0022","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","article-title":"Advances in NK cell production","volume":"19","author":"Fang","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jcyt.2026.102079_bib0023","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s13402-023-00909-3","article-title":"NK cells as powerful therapeutic tool in cancer immunotherapy","volume":"47","author":"Huang","year":"2024","journal-title":"Cell Oncol (Dordr)."},{"issue":"3","key":"10.1016\/j.jcyt.2026.102079_bib0024","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10561-022-10056-y","article-title":"Cord blood derived NK cells activated in counter with tumor cells","volume":"24","author":"Valipour","year":"2023","journal-title":"Cell Tissue Bank"},{"key":"10.1016\/j.jcyt.2026.102079_bib0025","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2016.00504","article-title":"Manufacturing natural killer cells as medicinal products","volume":"7","author":"Chabannon","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102079_bib0026","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jcyt.2016.02.006","article-title":"Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: clinical implications for cancer treatment","volume":"18","author":"Oyer","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102079_bib0027","first-page":"5224","article-title":"Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells","volume":"11","author":"Mark","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102079_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1304689","article-title":"Optimizing the cryopreservation and post-thaw recovery of natural killer cells is critical for the success of off-the-shelf platforms","volume":"14","author":"Saultz","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102079_bib0029","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00262-017-2112-x","article-title":"Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells","volume":"67","author":"Nham","year":"2018","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:17:17Z","timestamp":1782199037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926000411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1465324926000411"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102079","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Umbilical cord blood\u2212derived natural killer cells as a viable and potent source for adoptive cell therapy","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the International Society for Cellular Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102079"}}